Item 2. Unregistered Sales of Equity Securities
Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Purchases of Equity Securities by the Registrant
The following table provides information on our share repurchases during the three months ended June 30, 2024:
Issuer Purchases of Equity Securities
Period Total Number
of Shares Purchased Average Price
Paid Per Share (1)
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (2)
Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs (1)
April 1, 2024 – April 30, 2024 — $ — — $ 150,000,000
May 1, 2024 – May 31, 2024 837,240 $ 29.86 837,240 $ 125,000,000
June 1, 2024 – June 30, 2024 — $ — — $ 125,000,000
Total 837,240 $ 29.86 837,240 $ 125,000,000
(1) The average price paid per shares excludes $0.1 million of excise tax incurred on share repurchases for the three months ended June 30, 2024. The remaining authorization outstanding for repurchases of common stock also exclude the excise tax incurred.
(2) Our Board of Directors has authorized the repurchase of common stock under a share repurchase program adopted and announced in May 2024. The share repurchase program authorizes the Company to purchase up to an aggregate of $150.0 million of the Company’s outstanding common stock. Repurchases under this program may be made at management’s discretion on the open market or through privately negotiated transactions, including plans that comply with Rule 10b5-1 under the Exchange Act. The share repurchase program may be suspended or discontinued at any time by the Company and has an expiration date of December 31, 2026.
The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including our stock price, corporate and regulatory requirements, tax implications, restrictions under our debt obligations, other uses for capital, impacts on the value of remaining shares, and market and economic conditions.
Refer to Note 10, Stockholders’ Equity , to our condensed consolidated financial statements included herein for more information on our share repurchases.
Pacira BioSciences, Inc. | Q2 2024 Form 10-Q | Page 50
Table of Contents
Item 3. DEFAULTS UPON SENIOR SECURITIES
None.
Item 4. MINE SAFETY DISCLOSURES
Not applicable.
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.